PULMATRIX INC (PULM)
US74584P3010 - Common Stock
We assign a fundamental rating of 3 out of 10 to PULM. PULM was compared to 194 industry peers in the Pharmaceuticals industry. PULM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PULM is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year PULM has reported negative net income.
In the past year PULM has reported a negative cash flow from operations.
PULM had negative earnings in each of the past 5 years.
PULM had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
PULM's Return On Assets of -68.69% is on the low side compared to the rest of the industry. PULM is outperformed by 72.92% of its industry peers.
Looking at the Return On Equity, with a value of -81.44%, PULM is in line with its industry, outperforming 42.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.69% | ||
| ROE | -81.44% | ||
| ROIC | N/A |
ROA(3y)-42.44%
ROA(5y)-47.01%
ROE(3y)-62.76%
ROE(5y)-91.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for PULM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PULM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PULM has been increased compared to 1 year ago.
PULM has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PULM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -21.89, we must say that PULM is in the distress zone and has some risk of bankruptcy.
PULM's Altman-Z score of -21.89 is on the low side compared to the rest of the industry. PULM is outperformed by 87.50% of its industry peers.
There is no outstanding debt for PULM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -21.89 |
ROIC/WACCN/A
WACC9.07%
2.3 Liquidity
A Current Ratio of 6.33 indicates that PULM has no problem at all paying its short term obligations.
PULM has a better Current ratio (6.33) than 71.88% of its industry peers.
PULM has a Quick Ratio of 6.33. This indicates that PULM is financially healthy and has no problem in meeting its short term obligations.
PULM has a better Quick ratio (6.33) than 72.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.33 | ||
| Quick Ratio | 6.33 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 29.30% over the past year.
The Revenue has grown by 20.23% in the past year. This is a very strong growth!
PULM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 117.48% yearly.
EPS 1Y (TTM)29.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.07%
Revenue 1Y (TTM)20.23%
Revenue growth 3Y-16.71%
Revenue growth 5Y117.48%
Sales Q2Q%-78.89%
3.2 Future
The Earnings Per Share is expected to grow by 22.73% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 40.85% on average over the next years. This is a very strong growth
EPS Next Y-18.91%
EPS Next 2Y-14.37%
EPS Next 3Y12.08%
EPS Next 5Y22.73%
Revenue Next Year1%
Revenue Next 2Y1%
Revenue Next 3Y33.81%
Revenue Next 5Y40.85%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PULM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PULM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PULM's earnings are expected to grow with 12.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.37%
EPS Next 3Y12.08%
5. Dividend
5.1 Amount
No dividends for PULM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PULMATRIX INC
NASDAQ:PULM (11/15/2024, 8:00:00 PM)
After market: 6.56 0 (0%)6.56
+1.86 (+39.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap23.94M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.69% | ||
| ROE | -81.44% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.33 | ||
| Quick Ratio | 6.33 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)29.3%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-18.91%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)20.23%
Revenue growth 3Y-16.71%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y